Promising Mucoadhesion Results from Polyrizon's Hydrogel
Enhanced mucoadhesion may lead to improved outcomes for opioid overdose situations.
Polyrizon Ltd. (NASDAQ: PLRZ), a pioneering biotechnology company known for its intranasal product development, has released exciting new preclinical results indicating that their innovative naloxone hydrogel adheres to nasal tissues more effectively than the current intranasal naloxone spray on the market. This discovery could have significant implications for emergency medical responses to opioid overdoses.
Research Highlights: Hydrogel Versus Commercial Product
In a thorough research study using an established ex-vivo rabbit nasal mucosa model, scientists tested both Polyrizon’s hydrogel formulation and a leading commercial product. They applied each compound to mucosal tissue, followed by a wash with Simulated Nasal Electrolyte Solution (SNES) for 30 minutes. The analysis revealed that Polyrizon’s hydrogel retained a higher concentration of a fluorescence marker compared to the commercial counterpart, achieving statistically significant results (p < 0.0001, two-way ANOVA). This indicates that Polyrizon's hydrogel displays remarkable mucosal retention capabilities.
Importance of Mucoadhesion in Drug Delivery
Understanding mucoadhesion’s impact on intranasal drug delivery is crucial, especially for urgent treatments like opioid overdose reversal. A hydrogel that maintains a strong presence in the nasal cavity can enable more efficient absorption of medication, which may translate to a faster onset of action during critical moments.
Potential Benefits of the Trap and Target™ Hydrogel
Tomer Izraeli, CEO of Polyrizon, articulated, "These findings emphasize the potential of our Trap and Target™ (T&T) hydrogel technology, showcasing its distinct advantages over current offerings in intranasal drug administration. The significant improvement in mucoadhesion represents a vital achievement as we progress with our Naloxone program." This consensus affirms that enhancing mucoadhesion not only ensures better absorption, but also enhances patient safety during use.
Building on Stability Results
This recent dataset complements earlier reported stability results demonstrating that Polyrizon's formulation retains its efficacy under various conditions. The combination of stability and superior mucoadhesion highlights the likelihood of Polyrizon's T&T technology delivering a safe, effective, and consistent intranasal Naloxone solution.
About Polyrizon
Polyrizon is a biotechnology company engaged in crafting advanced medical device hydrogels, particularly those delivered through nasal sprays. These hydrogels create a thin shield within the nasal cavity that acts as a barrier against viruses and allergens, thereby protecting nasal epithelial tissue. A key technology, known as Capture and Contain™ (C&C), is being further developed to enhance bioadhesion and retention of the hydrogels to optimize drug delivery efficiency through the nasal route. Additionally, Polyrizon is exploring their T&T technology for the delivery of active pharmaceutical ingredients (APIs), which is currently in the preclinical stage of development.
Frequently Asked Questions
What is Polyrizon's focus area?
Polyrizon is dedicated to developing innovative intranasal drug delivery systems, specifically hydrogels that improve treatment efficiency and safety.
What are the advantages of Polyrizon's naloxone hydrogel?
The naloxone hydrogel shows improved mucoadhesion, which may enhance drug absorption and offer faster action during opioid overdose emergencies.
What results were observed from the recent research study?
Polyrizon's hydrogel exhibited significantly greater mucosal retention compared to a marketed intranasal naloxone product, supporting its potential for improved delivery.
How does mucoadhesion impact drug delivery?
Prolonged mucoadhesion allows for better absorption at the site of delivery, crucial for fast-acting emergency medicines like naloxone.
What technologies is Polyrizon developing?
Polyrizon is developing the Capture and Contain™ technology for creating protective nasal hydrogels, along with the Trap and Target™ technology for effective active ingredient delivery.
